ethics roundupThursday 16 July

Trump stock trades, organ sacks, and gene editing

Today's ethics coverage spans three distinct threads: a sitting president's potential insider trading, a startup's dystopian organ-growing scheme, and the deaf community's exclusion from gene-editing debates. Each raises uncomfortable questions about power, consent, and who gets to decide what's ethical.

In today's edition: Presidential trading and Organ sacks and gene editing, plus quick bites.

Presidential trading

The biggest story today is the CNN investigation into Trump's stock promotions on Truth Social, which raises clear ethical and legal red flags.

politicalwire.com

0
White House Staffer Wagered On Trump’s Remarks

A White House staffer is under investigation for betting on prediction markets tied to Trump's remarks. It's a smaller story but reinforces the day's theme of insider advantage.

Organ sacks and gene editing

Two very different bioethics stories: a startup trying to grow organs in brainless humanoids, and the deaf community pushing back against gene-editing assumptions.

theguardian.com · 2 min

0
Deaf people excluded from gene-editing debate

The British Deaf Association says deaf people have been excluded from gene-editing debates, and polling doesn't support using it for non-life-threatening conditions. A direct challenge to the 'inevitability' narrative.

Quick bites